Meet Our Scientific Director & Founder
Scientific Director - Ana Cristina Andreazza, Pharm, PhD
Dr. Andreazza is an Associate Professor in the Departments of Pharmacology & Toxicology and Psychiatry and holds a holding Tier II Canada Research Chair in Molecular Pharmacology of Mood Disorders. She is cross-appointed as a collaborator Scientist at the Centre for Addiction and Mental Health. Dr. Andreazza is an Advisor for the Dauten Family Center for Bipolar Treatment Innovation at Massachusetts General Hospital, a consultant for the Bipolar Biobank at Mayo Clinic and as a member of the Board of Directors from the International Society of Bipolar Disorder.
Dr. Andreazza received PhD in Biochemistry from the Federal University of Rio Grande do Sul, RS, Brazil. She has published over 140 research articles with an h-index factor of 45. She is the recipient of several prestigious research awards, including the 2018 Canada Top 40 Under 40 and has received funding from the Brain and Behavior Foundation (NARSAD), the Canadian Institutes for Health Research, the Ontario Mental Health Foundation and the Ontario Ministry of Research and Innovation. Her research focuses on the understanding of the role of redox modulations and mitochondrial dysfunction in mental illness, especially in mood disorders.
Dr. Andreazza research focuses on the understanding of the role of mitochondrial function in mental illness, especially in mood disorders. As neurons depend on mitochondrial function, dysfunctional mitochondrial during neurodevelopment is expected to impact neurotransmission with potentially crucial implications for mood disorders. Currently, Dr. Andreazza is evaluating the impact of mitochondrial dysfunction on neurotransmission using 3D brain organoids generated from induced pluripotent stem cells from patients with bipolar disorder and/or mitochondrial disease.
To accelerate the discovery of effective therapeutic approaches to treat mitochondrial dysfunction/disease, Dr. Andreazza founded the mitoNET.ca with the objective of uniting researchers from different medical fields with a common interest in unveiling the role of mitochondrial function and genetics in human diseases.
Meet Our Co-Scientific Directors
Co-Scientific Director - Ingrid Tein, BSc, MD, FRCP(C)
Dr. Tein obtained her BSc and MD from the University of Toronto. She completed her paediatric and paediatric neurology training at The Hospital for Sick Children (SickKids) in Toronto. She did her post-doctoral research training in fatty acid oxidation disorders at Hôpital Necker-Enfants Malades, Faculté de Médécine in Paris with Prof. J.M. Saudubray and in the Dept of Neurology at Columbia University, New York with Prof. Darryl DeVivo and Prof. Salvatore DiMauro, Dr. Tein returned to SickKids as a Staff Neurologist and founded the Neurometabolic Clinic, Neuroinvestigational Unit and Neurometabolic Research Laboratory. She was recipient of the Samuel Lunenfeld Foundation Scholarship in 1991 and Medical Research Council of Canada Scholarship in 1992. Dr. Tein is Associate Professor of Paediatrics, Laboratory Medicine and Pathobiology at the University of Toronto and was promoted to Senior Scientist in the SickKids Research Institute in 2003.
Dr. Tein directs the Neurometabolic Clinic for the investigation and treatment of children with neurometabolic diseases including mitochondrial and fatty acid oxidation disorders. She conducts prospective cross-over trials including ergometric investigation of metabolic myopathies. The goal of her research laboratory is the biochemical and molecular investigation of genetic fatty acid oxidation defects and development of in vitrodisease models to understand pathophysiological mechanisms. She has identified novel clinical and biochemical phenotypes and genotypes, developed new diagnostic screening tests and novel treatment strategies aimed at bypassing/correcting the metabolic block which have decreased long-term morbidity and mortality and have been successfully implemented internationally. Her research has been supported by the MRC, CIHR, Heart and Stroke Foundation, MDA and UMDF. She is author of over 140 research articles and reviews and has given over 310 invited talks including 155 international plenary talks.
Dr. Tein has served as Director of the Adam Barsky Lectureship in Mitochondrial Diseases since 1995 and Sarah Langer Mitochondrial Studentships since 2000 and founded the Neurometabolic Fellowship training program in 2007. She was Co-Chair of the international NINDS Mitochondrial Diseases Common Data Element Working Group (2014-2017) for development of a neurological toolkit for RCTs. She has won prestigious international awards and is President of the International Child Neurology Association (2014-2018) to promote excellence in clinical care, education and research in Child Neurology internationally including awareness of mitochondrial diseases.
Co-Scientific Director - Tania Bubela, BSc, JD, PhD
Dr. Bubela was appointed Dean of the Faculty of Health Sciences at Simon Fraser University in September 2017. Prior to that appointment, she was Professor and Associate Dean (Research) in the School of Public Health and Adjunct Professor in Alberta Business at the University of Alberta (UofA), Canada. She joined the faculty of the UofA in 2004 after clerking for The Honourable Louise Arbour at the Supreme Court of Canada, articling at Field Law LLP in Edmonton, and being called to the bar (Law Society of Alberta) in 2005.
Her research program in intellectual property and health law, focused on translational biomedical research, brings together her legal training and a PhD in biology and expertise in genetics and molecular biology. Her research program focuses on large collaborative science networks in genomics, gene therapy, and stem cell biology. It addresses barriers to the development and effective translation of new technologies. These are varied and include ethical issues, effective communication of risks and benefits among stakeholder groups, commercialization and regulation. She provides advice for governmental health and science agencies as well as life sciences research communities, and patient organisations.
Her research is funded by the Canadian Institutes of Health Research, BioCanRx, the Canadian Stem Cell Network, Genome Canada, and Alberta Innovates - Health Solutions, among others. She co-leads the PACEOMICS program on the development of cost-effective personalized medicine and the Alberta Ocular Gene Therapy Team, which is developing novel gene therapies and conducting a phase I clinical trial of the NighstaRx AAV2-REP1 product for choroideremia.
She has over 100 publications in law, ethics and science policy journals including articles in Nature, Nature Biotechnology, Cell Stem Cell, PLoS Biology, Trends in Biotechnology, American Journal of Bioethics and Science Translational Medicine.